CliffBio
small molecule

JAKAFI XR

RUXOLITINIB PHOSPHATE

Loss of exclusivityJanuary 2034latest FDA-listed patent expiry
CompanyIncyte →View the full company profile on CliffBio

Drug detail

Brand nameJAKAFI XR
Active ingredientRUXOLITINIB PHOSPHATE
StrengthEQ 55MG BASE
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalMay 2026
Marketing statusRX

Listed patents

PatentExpiresType
11337927January 2034use U-3226
11576865November 2033product
11576864November 2033use U-3226
10874616November 2033product
11896717November 2033product
11213528June 2028product
10016429June 2028use U-3230
8822481June 2028use U-3226
8722693June 2028substance, product
8829013June 2028use U-3228
8415362December 2027substance, product
7598257December 2027substance, product
8530485December 2026product
9206187December 2026use U-3228
9814722December 2026use U-3230
9079912December 2026use U-3226
11744832December 2026use U-3230

More from Incyte

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

JAKAFI XR patent cliff — loss of exclusivity January 2034 | CliffBio